Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (32,367)	$ (69,463)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	147	59
Amortization of right-of-use assets	603	519
Amortization of debt issuance costs	0	1,884
Stock-based compensation	667	10,019
PPP Loan forgiveness	0	(905)
Change in fair value of convertible notes	0	7,469
Change in fair value of Series C convertible preferred stock	0	3,592
Change in fair value of warrant liability	(90)	3,191
Earnings from equity method investment	(151)	(76)
Distribution from equity investment	0	36
Changes in operating assets and liabilities:
Grants receivable	806	0
Prepaid expenses and other current assets	194	4,050
Other assets	31	(33)
Accounts payable	(2,529)	2,072
Accrued expenses	1,689	2,182
Lease liabilities	(663)	(506)
Deferred revenue	(2,301)	(2,371)
Net cash used in operating activities	(33,964)	(38,281)
Cash flows from investing activities:
Purchases of fixed assets	0	(346)
Net cash used in investing activities	0	(346)
Cash flows from financing activities:
Net proceeds from issuance of common stock upon initial public offering and Concurrent Private Placement, net of discount and commissions	0	110,560
Payment of deferred offering costs	0	(3,073)
Fractional share payments related to the forward stock split	0	(10)
Taxes paid related to net share settlement upon vesting of restricted stock awards	(2)	(2,458)
Proceeds from RSU settlement	0	21
Payment of financing obligation	(43)	0
Exercise of warrants	0	861
Exercise of stock options	0	866
Net cash (used in) provided by financing activities	(45)	106,767
Effect of foreign currency on cash	396	(11)
Net (decrease) increase in cash and cash equivalents	(33,613)	68,129
Cash and cash equivalents at the beginning of the period	88,756	34,607
Cash and cash equivalents at the end of the period	55,143	102,736
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	0	624
Fixed assets purchased in accrued expenses or accounts payable	0	32
IPO
Supplemental disclosure of noncash investing and financing activities:
Conversion of convertible notes into stock	0	58,179
Conversion of Series C preferred stock into common stock upon initial public offering	0	35,754
Net exercise of warrants upon initial public offering	0	13,509
Non-IPO Related Stock Transactions
Supplemental disclosure of noncash investing and financing activities:
Conversion of convertible notes into stock	$ 0	$ 460